Analysis of Giant Biogene (02367.HK) Making It to Hong Kong Stock Hot List

Giant Biogene (02367.HK) made it to the Hong Kong Stock Hot List on December 22, 2025, mainly driven by two positive events:

The company signed an agreement with Sweden’s Nordberg Medical to jointly promote the global development and commercialization of recombinant collagen in the medical aesthetics and biomedical fields. Nordberg Medical has regulatory approvals in 33 markets and a direct sales network covering more than 20 countries, providing key support for Giant Biogene’s global layout [1].

On the day it entered the hot list, the company repurchased 400,000 shares at HK$35.86-36.34 per share, costing HK$14.4297 million. Earlier, on December 2, it had announced a large-scale repurchase plan: intending to repurchase no more than 104 million shares (accounting for 10% of the total share capital), with an estimated capital requirement of about HK$3.7 billion, demonstrating the management’s confidence in long-term development [2][4].

Price and Trading Volume: On December 22, 2025, the stock price rose 1.63% to close at HK$36.06, and the repurchase action directly supported the stock price [2]. Market Sentiment: In addition to repurchases, the controlling shareholder increased holdings by a total of 3.6666 million shares (costing HK$178 million), combined with the fundamental support of H1 2025 revenue of RMB 3.113 billion (+22.52%) and net profit of RMB 1.182 billion (+20.23%), which strengthened investment attractiveness [4].

1. Track Leader Position Consolidated
   : As a global leader in recombinant collagen, the company’s core brands “KFM” and “Koligen” performed prominently; this cooperation and repurchase further reinforced its leading position [4].
2. Overseas Expansion Strategy Accelerated
   : The partnership with Nordberg Medical marks the company’s shift from product export to ecosystem export, unlocking global market space [1].
3. Shareholder Confidence Signal
   : The combination of large-scale repurchase (10% of share capital) and the controlling shareholder’s increased holdings conveys recognition of the company’s value to the market [2][4].

:

• The recombinant collagen market continues to grow; global cooperation is expected to boost market share [1].
• High dividend yield (3.42%) enhances long-term investment appeal [4].

:

• H1 2025 performance growth slowed compared to 2024; attention should be paid to the impact of the consumption environment on the medical aesthetics track [4].
• Global cooperation requires regulatory approval and market expansion; actual results are uncertain [1].
• Data limitations: Real-time transaction data and complete recent trends are temporarily missing; follow-up fluctuations need to be monitored [2].

• Stock Code: 02367.HK
• Sector: Biotech/Medical Aesthetics
• Hot List Catalysts: Global Strategic Cooperation + Share Repurchase
• Closing Price on December 22, 2025: HK$36.06
• Short-term Key Prices: Support Level HK$35.58-35.86, Resistance Level HK$36.34

All data and analysis are from the following sources: [1][2][4]